ClinicalTrials.gg
CompletedNCT03184870Updated Oct 9, 2025Results posted

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

A Phase 1/2 interventional study of BMS-813160 and Nivolumab in Colorectal Cancer and Pancreatic Cancer, sponsored by Bristol-Myers Squibb. Completed at 40 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 3 of them phase 3. Colorectal Neoplasms · Bristol-Myers Squibb.

Enrollment
9th of 27
332 · median 171
Started
2017
the only one that year
Phase 1/2
10 of 29
2 open now
Registered
12th of 29
by date

Among the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2017, is one of 10 in phase 1/2, and was the 12th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Colorectal Neoplasms by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.

03

Conditions studied

  • Colorectal Cancer
  • Pancreatic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Must have colorectal or pancreatic cancer
  • (ECOG) performance status of ≤1
  • Ability to swallow pills or capsules
  • Required to undergo mandatory pre and on-treatment
  • Adequate marrow function
  • Adequate other organ functions
  • Ability to comply with study visits, treatment, procedures, pharmacokinetic (PK) and pharmacodynamic (PD) sample collection, and required study follow-up

Exclusion criteria

Exclusion Criteria:

  • Histology other than adenocarcinoma (neuroendocrine or acinar cell)
  • Suspected, known, or central nervous system (CNS) (Imaging required only if participants are symptomatic)
  • Active, known or suspected disease
  • Condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study treatment administration
  • Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
  • Prior treatment with cysteine-cysteine chemokine receptor 2 (CCR2) and/or cysteine-cysteine chemokine receptor 5 (CCR5) inhibitors, programmed death-1 receptor (), programmed death-ligand 1 [PD(L)-1] or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies
  • History of allergy to study treatments or any of its components of the study arm that participant is enrolling

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
332 participants (actual)

Study arms

  • Experimental
    Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI

    FOLFIRI: FOL (folinic acid \[leucovorin\]) F (fluorouracil \[5-fluorouracil\]) IRI (irinotecan \[CAMPTOSAR\])

    Drug: BMS-813160 · Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan

  • Experimental
    Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel

    Drug: BMS-813160 · Drug: Nab-paclitaxel · Drug: Gemcitabine

  • Experimental
    Part 1 Arm C [2L Pancreatic & 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab

    2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable

    Drug: BMS-813160 · Biological: Nivolumab

  • Experimental
    Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI

    Drug: BMS-813160 · Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan

  • Experimental
    Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI

    Drug: BMS-813160 · Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan

  • Experimental
    Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI

    Drug: 5-fluorouracil (5-FU) · Drug: Leucovorin · Drug: Irinotecan

  • Experimental
    Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel

    Drug: BMS-813160 · Drug: Nab-paclitaxel · Drug: Gemcitabine

  • Experimental
    Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel

    Drug: BMS-813160 · Biological: Nivolumab · Drug: Nab-paclitaxel · Drug: Gemcitabine

  • Experimental
    Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel

    Drug: Nab-paclitaxel · Drug: Gemcitabine

  • Experimental
    Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab

    Drug: BMS-813160 · Biological: Nivolumab

  • Experimental
    Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab

    Drug: BMS-813160 · Biological: Nivolumab

  • Experimental
    Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy

    Drug: BMS-813160

  • Experimental
    Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy

    Drug: BMS-813160

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Adverse Events (AEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 100 days post last dose, up to approximately 3 years

  2. Number of Participants Experiencing Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: From first dose up to 100 days post last dose, up to approximately 3 years

  3. Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)

    Dose-limiting toxicities (DLTs) are severe adverse effects (AEs) that are attributed to BMS-813160 or the combination regimen and define the maximum tolerated dose of a medicine. DLTs will be defined based on the incidence, duration and grade of AEs for which no alternate cause can be identified. AEs will be evaluated according to the NCI CTCAE v4.03. The incidence of DLT(s) during the first 6 weeks of treatment in Part 1 (the DLT evaluation period) and 4 weeks for Part 2 will be used.

    Time frame: From first dose up to 100 days post last dose, up to approximately 3 years

  4. Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

    An Adverse Event (AE) leading to discontinuation is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment that leads to the discontinuation of study treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 100 days post last dose, up to approximately 3 years

  5. Number of Participants Who Died

    The number of participants who died within 100 days after receiving their last dose

    Time frame: From first dose up to 100 days post last dose, up to approximately 3 years

  6. Number of Participants Experiencing Laboratory Abnormalities

    The number of participants experiencing laboratory abnormalities in pre-specified selected parameters during the treatment period per CTCAE (Version 4). Laboratory abnormalities are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

    Time frame: From first dose up to 100 days post last dose, up to approximately 3 years

  7. Vital Signs

    Vital sign measurements at baseline and at the end of treatment. Baseline evaluations will be defined as evaluations with a date on or prior to the day of first dose of study treatment.

    Time frame: From first dose to 100 days post last dose, up to approximately 3 years

  8. Number of Participants With Out-of-Range Electrocardiograms (ECG)

    The number of participants with ECG measurements outside of the range pre-specified in the protocol.

    Time frame: From baseline up to 100 days post last dose

  9. Percent Change in Regulatory T Cells (Treg) in Tumor Samples

    The percent change in Regulatory T Cells (Treg) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.

    Time frame: From first dose up to prespecified timepoints listed below (C0D7; C0D14; C1D1; C1D15; C1D16; C1D28; C2D1)

  10. Percent Change in Tumor-Associated Macrophages (TAMs) in Tumor Samples

    The percent change in Tumor-Associated Macrophages (TAMs) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.

    Time frame: From first dose up to prespecified timepoints listed below (C0D7; C0D14; C1D1; C1D15; C1D16; C1D28; C2D1)

  11. Objective Response Rate (ORR)

    Objective Response Rate (ORR) as determined by Investigator was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. Progression is defined as at least 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. Complete response (CR)= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR)= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose until disease progression, or the last response recorded (up to approximately 5 years)

  12. Duration of Response (DoR)

    Duration of Response (DOR), computed for all treated participants with a best overall response (BOR) of complete response (CR) or partial response (PR), is defined as the time between the date of first response (CR or PR) and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurs first, ie., DOR = disease progression date/death date -first response date + 1. For participants who remain alive and have not progressed, DOR will be censored on the date of their last tumor assessment. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first dose up to date of disease progression or death, whichever occurs first (up to approximately 5 years)

  13. Progression Free Survival (PFS) Rate at 24 Weeks

    PFS rate is defined as the proportion of participants who were progression free at Week 24. PFS is defined as the time from first dose to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Progression is defined at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. Complete response (CR)= Disappearance of all target lesions. Pathological lymph nodes must have short axis reduction to \< 10 mm. Partial response (PR)= At least 30% decrease in sum of diameters of target lesions. Participants who died w/o prior progression were considered progressed on death date. Those alive and not progressed were censored on the last tumor assessment date. Those who started subsequent therapy without reported progression were censored at last tumor assessment prior to subsequent therapy. Those without post-baseline tumor assessment and alive were censored at first dose.

    Time frame: From first dose up to Week 24

Secondary outcomes

  1. Maximim Concentration (Cmax)

    Cmax is defined as the maximum plasma concentration of the analytes at the prespecified timepoints.

    Time frame: From first dose up to the prespecified timepoints, C0D1, C0D14, and C2D1

  2. Time to Maximum Concentration (Tmax)

    Tmax is defined as the time in hours of the maximum observed plasma concentration

    Time frame: From first dose up to the prespecified timpoints, C0D1, C0D14, AND C2D1

  3. Trough Observed Plasma Concentration (Ctrough)

    Ctrough is defined as the concentration reached by a drug immediately before the next dose is administered

    Time frame: From first dose up to prespecified timepoints, C0D1, C5D1, C0D1, C1D15, C5D1

  4. Area Under Curve (AUC) 0-8

    Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose

    Time frame: From first dose up to prespecified timepoints- C0D1, C2D1

  5. Area Under Curve (AUC) 0-24

    Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose

    Time frame: From first dose up to prespecified timepoints-C0D1, C2D1

  6. Apparent Total Body Clearance (CLT/F)

    The total body clearance (CLT/F) is defined as the volume of plasma completely cleared of drug per unit time

    Time frame: From first dose up to prespecified timepoints-C0D1, C2D14

  7. Renal Clearance (CLR)

    Renal clearance is defined as the rate at which the analytes were removed from the plasma by the kidneys.

    Time frame: From first dose up to prespecified timepoints-C0D1, C0D14

  8. Number of Participants Who Were Anti-Drug Antibody (ADA) Positive

    The number of participants who are anti-drug antibody positive. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. ADA-positive sample is in a participant who is baseline ADA negative or with an ADA titer to be at least 4-fold or greater than baseline positive titer.

    Time frame: From first dose up to prespecified timepoints-C1D1, C1D15, C2D1, C3D1, C5D1, C9D1

07

Results

Posted Oct 9, 2025

Participant flow

Initial Treatment
Participant flow — Initial Treatment
MilestonePart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Started108101187711123232263535322424
Completed000000000000000000
Not completed108101187711123232263535322424
Withdrew: Death66886667122628103334262018
Withdrew: Other reasons220100020042200102
Withdrew: Lost to follow-up200111020020220022
Withdrew: Withdrawal by subject002110100002301522
Withdrew: Moved to crossover treatment000000000000900000
Crossover Treatment
Participant flow — Crossover Treatment
MilestonePart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Started000000000000000009
Completed000000000000000000
Not completed000000000000000009
Withdrew: Other reasons000000000000000002
Withdrew: Death000000000000000007

Outcome measures

PrimaryNumber of Participants Experiencing Adverse Events (AEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 100 days post last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Number of Participants Experiencing Adverse Events (AEs)108101187711123232253535312332
PrimaryNumber of Participants Experiencing Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe), requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
From first dose up to 100 days post last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Experiencing Serious Adverse Events (SAEs)
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Number of Participants Experiencing Serious Adverse Events (SAEs)5557566612121262422151719
PrimaryNumber of Participants Experiencing Dose-Limiting Toxicities (DLTs)

Dose-limiting toxicities (DLTs) are severe adverse effects (AEs) that are attributed to BMS-813160 or the combination regimen and define the maximum tolerated dose of a medicine. DLTs will be defined based on the incidence, duration and grade of AEs for which no alternate cause can be identified. AEs will be evaluated according to the NCI CTCAE v4.03. The incidence of DLT(s) during the first 6 weeks of treatment in Part 1 (the DLT evaluation period) and 4 weeks for Part 2 will be used.

Time frame:
From first dose up to 100 days post last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)002200000000001000
PrimaryNumber of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation

An Adverse Event (AE) leading to discontinuation is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment that leads to the discontinuation of study treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 100 days post last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation20160101011062128342
PrimaryNumber of Participants Who Died

The number of participants who died within 100 days after receiving their last dose

Time frame:
From first dose up to 100 days post last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Who Died
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Number of Participants Who Died66886667122628173334262025
PrimaryNumber of Participants Experiencing Laboratory Abnormalities

The number of participants experiencing laboratory abnormalities in pre-specified selected parameters during the treatment period per CTCAE (Version 4). Laboratory abnormalities are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.

Time frame:
From first dose up to 100 days post last dose, up to approximately 3 years
Reported as:
Count of participants · Participants
Number of Participants Experiencing Laboratory Abnormalities
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
ALANINE AMINOTRANSFERASE (ALT), LOCAL LAB (U/L) - Abnormal High2457213611159102428241013
ASPARTATE AMINOTRANSFERASE (AST), LOCAL LAB (U/L) - Abnormal High2457335511151292126241219
Total Bilirubin (UMOL/L) - Abnormal High245211431155287567
Neutrophils (Absolute) (10^9/L) - Abnormal Low645921120025201822252514
PLATELET COUNT (10^9/L) - Abnormal Low515521130011158242826105
PrimaryVital Signs

Vital sign measurements at baseline and at the end of treatment. Baseline evaluations will be defined as evaluations with a date on or prior to the day of first dose of study treatment.

Time frame:
From first dose to 100 days post last dose, up to approximately 3 years
Reported as:
Mean · mmHg
Vital Signs
mmHgPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Systolic Blood Pressure (mmHg) - End of Treatment133.0 ± NA129.7 ± 6.7130.2 ± 21.8143.0 ± 34.0114.0 ± 15.0125.0 ± 6.1140.3 ± 18.0124.0 ± 23.7151.0 ± NA107.0 ± NA126.0 ± 15.9113.0 ± NA113.0 ± NA123.2 ± 18.8128.9 ± 17.8118.8 ± 15.9112.6 ± 11.6123.1 ± 13.6
Systolic Blood Pressure (mmHg) - Follow-up140.0 ± 8.5124.5 ± 2.1100.0 ± NA143.0 ± 34.0140.0 ± 8.5108.0 ± NA148.0 ± NA129.5 ± 29.0——127.9 ± 13.2131.3 ± 20.6113.6 ± 8.1119.2 ± 15.1142.6 ± 16.0108.3 ± 30.1113.0 ± NA113.5 ± 6.4
Diastolic Blood Pressure (mmHg) - End of Treatment83.0 ± NA73.3 ± 7.275.4 ± 12.480.8 ± 17.769.6 ± 9.486.0 ± 18.289.7 ± 11.174.3 ± 11.386.0 ± NA67.0 ± NA79.0 ± 11.574.5 ± 3.575.0 ± NA69.2 ± 8.274.3 ± 8.670.2 ± 8.668.1 ± 6.574.3 ± 9.7
Diastolic Blood Pressure (mmHg)- Follow-up79.0 ± NA71.5 ± 14.859.0 ± NA—85.0 ± 2.869.0 ± NA98.0 ± NA72.5 ± 4.9——76.6 ± 14.676.1 ± 11.078.2 ± 7.368.0 ± 9.970.2 ± 10.566.7 ± 20.185.0 ± NA69.0 ± 2.8
PrimaryNumber of Participants With Out-of-Range Electrocardiograms (ECG)

The number of participants with ECG measurements outside of the range pre-specified in the protocol.

Time frame:
From baseline up to 100 days post last dose
Reported as:
Count of participants · Participants
Number of Participants With Out-of-Range Electrocardiograms (ECG)
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
QTcF INTERVAL (MSEC) < 4507810887710123127232630262431
QTcF INTERVAL (MSEC): 450 <= QTcF < 480300100010004264302
480<=QTcF<500 (MSEC)000100000000010000
QTcF>= 500 (MSEC)000000000010010000
QTcB INTERVAL (MSEC) < 45047857337122021151417192115
450<=QTcB<480 (MSEC)51131432001171014148318
480<=QTcB<500 (MSEC)101200120003043200
QTcB>= 500 (MSEC)000000000010020000
PrimaryPercent Change in Regulatory T Cells (Treg) in Tumor Samples

The percent change in Regulatory T Cells (Treg) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.

Time frame:
From first dose up to prespecified timepoints listed below (C0D7; C0D14; C1D1; C1D15; C1D16; C1D28; C2D1)
Reported as:
Median · Percent change in Treg
Percent Change in Regulatory T Cells (Treg) in Tumor Samples
Percent change in TregPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
FOXP3 - C0D726.6 (-67 to 180)-43.8 (-58 to -15)-22.9 (-74 to -14)156.4 (-12 to 177)57.3 (-76 to 116)-18.4 (-27 to -9)-92.2 (-94 to 27)96.4 (14 to 152)—101.0 (101 to 101)————————
FOXP3 - C0D1426.5 (-50 to 103)-19.8 (-78 to 53)60.0 (60 to 60)-41.6 (-67 to -16)-41 (-41 to -41)-26.5 (-57 to 249)180.2 (-60 to 421)-3.7 (-9 to 25)——————————
FOXP3 - C1D1————34.7 (-58 to 128)49 (49 to 49)147.4 (20 to 275)33.0 (-51 to 338)—31.0 (31 to 31)————————
FOXP3 - C1D15————-25.9 (-48 to -6)14.5 (-90 to 322)39.1 (4 to 74)-33 (-33 to -33)———-39.1 (-46 to -32)60 (60 to 60)113.6 (-1 to 228)—17.0 (-39 to 73)-64 (-64 to -64)—
FOXP3 - C1D16——————————-21 (-21 to -21)———————
FOXP3 - C1D28——————————-7.4 (-26 to 113)-77.0 (-93 to -61)12.0 (-73 to 152)-36.0 (-77 to -5)99.4 (-96 to 2199)-46.6 (-55 to 551)216.7 (98 to 363)-13.6 (-78 to 149)
FOXP3 - C2D1——————————305.2 (-73 to 683)————184 (184 to 184)-2.4 (-37 to 32)156.2 (13 to 299)
PrimaryPercent Change in Tumor-Associated Macrophages (TAMs) in Tumor Samples

The percent change in Tumor-Associated Macrophages (TAMs) were taken at prespecified timepoints. Baseline is defined as the last non-missing value prior to the first dosing.

Time frame:
From first dose up to prespecified timepoints listed below (C0D7; C0D14; C1D1; C1D15; C1D16; C1D28; C2D1)
Reported as:
Median · Percent change in TAM
Percent Change in Tumor-Associated Macrophages (TAMs) in Tumor Samples
Percent change in TAMPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
CD163 Positive - C0D7——————13.1 (2 to 808)-12.7 (-67 to 231)——————————
CD163 Positive - C0D14——————95.4 (34 to 157)133.6 (0 to 286)——————————
CD163 Positive - C1D1——————477.5 (334 to 621)22.1 (-28 to 520)——————————
CD163 Positive - C1D15——————7.6 (-37 to 53)-93 (-93 to -93)———89.8 (35 to 132)-61 (-61 to -61)145.7 (43 to 248)—60.3 (1 to 120)——
CD163 Positive - C1D16——————————1369 (1369 to 1369)———————
CD163 Positive - C1D28——————————-4.1 (-21 to 1072)-58.4 (-98 to -19)106.3 (-67 to 511)-14.7 (-57 to 91)65.5 (-31 to 666)1.0 (-96 to 61)——
CD163 Positive - C2D1——————————-58.3 (-94 to -22)————-41.3 (-61 to -33)—39.3 (-1 to 79)
CD68 Positive - C0D7——————-70.2 (-91 to 107)-17.1 (-64 to -2)——————————
CD68 Positive - C0D14——————57.7 (-12 to 128)7.9 (-8 to 24)——————————
CD68 Positive - C1D1——————294.2 (203 to 385)17.8 (-39 to 102)——————————
CD68 Positive - C1D15——————2.9 (-26 to 185)-26 (-26 to -26)———-4.0 (-27 to 58)81 (81 to 81)162.4 (150 to 175)—92.5 (20 to 165)——
CD68 Positive - C1D16——————————272 (272 to 272)———————
CD68 Positive - C1D28——————————31.5 (-60 to 296)-70.7 (-92 to -49)96.2 (-50 to 1106)-38.3 (-88 to 121)96.2 (-25 to 179)-4.3 (-46 to 102)——
CD68 Positive - C2D1——————————-26.9 (-50 to -4)————-40.0 (-54 to -33)—-66 (-66 to -66)
PrimaryObjective Response Rate (ORR)

Objective Response Rate (ORR) as determined by Investigator was defined as the number of participants with a best overall response of confirmed Complete Response (CR) or Partial Response (PR) (per RECIST 1.1 criteria) divided by the number of all treated participants. Progression is defined as at least 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. RECIST 1.1 = Response Evaluation Criteria in Solid Tumors. Complete response (CR)= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial response (PR)= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose until disease progression, or the last response recorded (up to approximately 5 years)
Reported as:
Number · Percent of participants
Objective Response Rate (ORR)
Percent of participantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Objective Response Rate (ORR)60.0 (26.2 to 87.8)25.0 (3.2 to 65.1)0 (0.0 to 30.8)18.2 (2.3 to 51.8)0 (0.0 to 36.9)0 (0.0 to 41.0)0 (0.0 to 41.0)0 (0.0 to 28.5)0 (0.0 to 97.5)0 (0.0 to 84.2)9.4 (2.0 to 25.0)9.4 (2.0 to 25.0)19.2 (6.6 to 39.4)22.9 (10.4 to 40.1)17.1 (6.6 to 33.6)21.9 (9.3 to 40.0)0 (0.0 to 14.2)8.3 (1.0 to 27.0)
PrimaryDuration of Response (DoR)

Duration of Response (DOR), computed for all treated participants with a best overall response (BOR) of complete response (CR) or partial response (PR), is defined as the time between the date of first response (CR or PR) and the date of first documented disease progression as determined by RECIST 1.1 or death due to any cause, whichever occurs first, ie., DOR = disease progression date/death date -first response date + 1. For participants who remain alive and have not progressed, DOR will be censored on the date of their last tumor assessment. CR= Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR= At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first dose up to date of disease progression or death, whichever occurs first (up to approximately 5 years)
Reported as:
Median · Weeks
Duration of Response (DoR)
WeeksPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Duration of Response (DoR)159.00 (47.00 to NA)NA (16.43 to NA)—NA (24.14 to NA)——————74.14 (32.14 to NA)56.57 (40.17 to NA)36.21 (16.14 to NA)32.14 (17.14 to 37.29)37.14 (14.14 to NA)20.57 (14.29 to 31.00)—NA (41.00 to NA)
PrimaryProgression Free Survival (PFS) Rate at 24 Weeks

PFS rate is defined as the proportion of participants who were progression free at Week 24. PFS is defined as the time from first dose to the date of first objectively documented disease progression or death due to any cause, whichever occurs first. Progression is defined at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. Complete response (CR)= Disappearance of all target lesions. Pathological lymph nodes must have short axis reduction to \< 10 mm. Partial response (PR)= At least 30% decrease in sum of diameters of target lesions. Participants who died w/o prior progression were considered progressed on death date. Those alive and not progressed were censored on the last tumor assessment date. Those who started subsequent therapy without reported progression were censored at last tumor assessment prior to subsequent therapy. Those without post-baseline tumor assessment and alive were censored at first dose.

Time frame:
From first dose up to Week 24
Reported as:
Number · Proportion of Participants
Progression Free Survival (PFS) Rate at 24 Weeks
Proportion of ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Progression Free Survival (PFS) Rate at 24 Weeks0.778 (0.3648 to 0.9393)NA (NA to NA)0.556 (0.2042 to 0.8045)0.800 (0.4087 to 0.9459)———NA (NA to NA)——0.357 (0.1699 to 0.5490)0.536 (0.3372 to 0.6996)0.691 (0.4361 to 0.8478)0.535 (0.3512 to 0.6888)0.636 (0.4495 to 0.7746)0.467 (0.2779 to 0.6358)—NA (NA to NA)
SecondaryMaximim Concentration (Cmax)

Cmax is defined as the maximum plasma concentration of the analytes at the prespecified timepoints.

Time frame:
From first dose up to the prespecified timepoints, C0D1, C0D14, and C2D1
Reported as:
Mean · ng/mL
Maximim Concentration (Cmax)
ng/mLPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
C0D1 - BMS-813160620.4 ± 250.602204.1 ± 961.90828.4 ± 458.032419.0 ± 1203.53486.3 ± 137.691896.3 ± 1421.891179.1 ± 605.50276.28 ± 141.9151580.0 ± NA807.0 ± NA————————
C0D1 - BMS-939429172.23 ± 103.837435.6 ± 284.14207.63 ± 142.559545.7 ± 218.8992.33 ± 50.015539.1 ± 465.93237.63 ± 188.28654.82 ± 23.716504.0 ± NA72.50 ± NA————————
C0D14 - BMS-813160927.1 ± 513.884152.5 ± 2010.231060.3 ± 830.043274.0 ± 884.15701.5 ± 284.591793.5 ± 1607.25653.3 ± 298.0880.00 ± 19.4081370.0 ± NA1680.0 ± 961.67————————
C0D14 - BMS-939429317.90 ± 290.209658.3 ± 143.17409.63 ± 382.471792.2 ± 503.92183.08 ± 190.050326.0 ± 241.83165.83 ± 92.91425.307 ± 16.6021498.0 ± NA265.40 ± 235.608————————
C2D1 - BMS-8131601153.1 ± 617.973280.0 ± 777.82————————903.9 ± 578.56357.55 ± 264.384—796.2 ± 472.48————
C2D1 - BMS-939429254.1 ± 140.73571.0 ± 376.42————————————————
SecondaryTime to Maximum Concentration (Tmax)

Tmax is defined as the time in hours of the maximum observed plasma concentration

Time frame:
From first dose up to the prespecified timpoints, C0D1, C0D14, AND C2D1
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax)
HoursPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
C0D1 - BMS-8131602.000 (0.50 to 4.00)0.500 (0.47 to 4.00)3.017 (2.00 to 4.02)2.492 (0.73 to 5.98)2.492 (0.52 to 11.92)2.983 (0.58 to 8.92)3.00 (0.50 to 6.00)1.992 (0.50 to 3.00)2.0 (2 to 2)3.950 (3.95 to 3.95)————————
C0D1 - BMS-9394293.500 (0.50 to 6.25)1.000 (0.50 to 4.00)3.508 (1.00 to 11.98)3.000 (0.73 to 5.98)3.000 (1.0 to 11.92)2.083 (1.08 to 8.92)3.000 (1.00 to 6.00)2.000 (0.98 to 4.00)2.0 (2 to 2)1.950 (1.95 to 1.95)————————
C0D14 - BMS-8131603.000 (0.55 to 3.03)1.825 (0.50 to 3.00)2.917 (0.92 to 15.70)2.983 (0.50 to 4.00)2.875 (0.50 to 3.00)2.0 (1 to 3)2.000 (1.00 to 3.02)1.00 (0.5 to 4.0)2.02 (2.02 to 2.02)2.542 (2.00 to 3.08)————————
C0D14 - BMS-9394293.000 (0.98 to 4.00)1.825 (0.50 to 3.00)3.000 (1.08 to 15.70)2.983 (1.00 to 4.00)2.875 (1.17 to 3.00)2.492 (1.98 to 3.00)3.000 (1.00 to 4.02)1.0 (1 to 6)2.02 (2.02 to 2.02)3.117 (2.00 to 4.23)————————
C2D1 - BMS-8131603.000 (0.98 to 4.23)1.000 (0.47 to 4.03)————————2.033 (0.50 to 14.10)2.067 (0.50 to 8.10)—3.992 (0.50 to 16.17)————
C2D1 - BMS-9394293.000 (2.00 to 4.23)1.000 (0.97 to 4.03)————————————————
SecondaryTrough Observed Plasma Concentration (Ctrough)

Ctrough is defined as the concentration reached by a drug immediately before the next dose is administered

Time frame:
From first dose up to prespecified timepoints, C0D1, C5D1, C0D1, C1D15, C5D1
Reported as:
Mean · ng/mL
Trough Observed Plasma Concentration (Ctrough)
ng/mLPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
C0D1 - BMS-813160283.70 ± 207.78484.30 ± 46.169292.0 ± 154.3174.05 ± 72.127157.28 ± 92.311137.0 ± NA57.10 ± 54.8715.485 ± 2.439577.40 ± NA154.05 ± 139.936————————
C5D1 - BMS-813160268.80 ± 216.882129.40 ± 89.944176.0 ± NA15.30 ± NA323.0 ± NA—————————————
C0D1 - BMS-939429172.63 ± 264.18731.40 ± 10.689180.88 ± 195.95972.95 ± 55.54247.60 ± 10.41231.50 ± NA63.45 ± 60.1754.950 ± 2.305290.30 ± NA71.65 ± 55.649————————
C1D15 - BMS 939429——————————191.33 ± 84.26624.106 ± 18.445275.7 ± 164.34116.04 ± 29.696145.00 ± 99.293—283.0 ± NA—
C5D1 - BMS-93942955.78 ± 31.87715.95 ± 4.172155.0 ± NA10.50 ± NA65.20 ± NA—————186.21 ± 131.45712.439 ± 6.9685195.0 ± NA191.44 ± 113.725222.65 ± 154.316——390.0 ± NA
SecondaryArea Under Curve (AUC) 0-8

Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose

Time frame:
From first dose up to prespecified timepoints- C0D1, C2D1
Reported as:
Mean · ug*h/mL
Area Under Curve (AUC) 0-8
ug*h/mLPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
C0D1 - BMS-8131602300.018 ± 976.46087069.265 ± 2452.42132725.390 ± 1365.35627884.381 ± 3968.49401534.932 ± 518.21726593.904 ± 3603.52863533.737 ± 1931.7752878.051 ± 535.31974440.313 ± NA3656.713 ± NA————————
C0D1 - BMS-939429652.848 ± 363.59251783.336 ± 856.0103936.394 ± 826.58072302.092 ± 1023.3978342.534 ± 157.13502147.888 ± 1415.6386942.398 ± 620.1018210.938 ± 106.53521919.228 ± NA411.410 ± NA————————
C2D1 - BMS-8131605348.973 ± 2506.255811967.560 ± 4586.3823————————4838.264 ± 2750.77561483.423 ± 1236.0374—3821.887 ± 2221.2474————
C2D1 - BMS-9394291410.415 ± 837.48952403.182 ± 1144.3271————————————————
SecondaryArea Under Curve (AUC) 0-24

Area Under Curve (AUC) is defined as the area under the plot of plasma concentration of a drug versus time after dosage measured at 8 hours post-dose

Time frame:
From first dose up to prespecified timepoints-C0D1, C2D1
Reported as:
Mean · ug*h/mL
Area Under Curve (AUC) 0-24
ug*h/mLPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
C0D1 - BMS-813160—9383.385 ± 2842.8397—11726.669 ± 6439.1376—10447.179 ± 2995.93474829.881 ± 2696.46681275.314 ± 799.8262—7687.658 ± NA————————
C0D1 - BMS-939429—2638.062 ± 977.2502—3991.522 ± 1636.3573—3905.941 ± 1852.84151660.159 ± 991.0121341.0396 ± 160.4425—940.294 ± NA————————
C2D1 - BMS-813160—17890.458 ± 9212.5646—————————2050.804 ± 997.6990——————
C2D1 - BMS-939429—3958.779 ± 1632.3781————————————————
SecondaryApparent Total Body Clearance (CLT/F)

The total body clearance (CLT/F) is defined as the volume of plasma completely cleared of drug per unit time

Time frame:
From first dose up to prespecified timepoints-C0D1, C2D14
Reported as:
Mean · mL/min
Apparent Total Body Clearance (CLT/F)
mL/minPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
C0D14 - BMS-8131601163.173 ± 588.1385744.746 ± 361.53901521.863 ± 1277.8075826.468 ± 300.17381602.009 ± 1123.8919961.379 ± 235.46221688.813 ± 1022.71604950.110 ± 781.01551135.947 ± NA1032.434 ± 850.2203————————
C2D1 - BMS-813160956.446 ± 596.7553683.958 ± 322.7045————————1115.087 ± 851.25131813.987 ± 1920.2627—1440.516 ± 733.5156————
SecondaryRenal Clearance (CLR)

Renal clearance is defined as the rate at which the analytes were removed from the plasma by the kidneys.

Time frame:
From first dose up to prespecified timepoints-C0D1, C0D14
Reported as:
Mean · mL/min
Renal Clearance (CLR)
mL/minPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
C0D1 - BMS-813160212.411 ± 191.8961275.309 ± 277.2659139.012 ± 107.2006165.327 ± 77.8766155.820 ± 119.3858181.930 ± 9.1130248.003 ± 82.6974236.781 ± 62.8689——————————
C0D1 - BMS-93942974.298 ± 44.8889175.109 ± 187.568368.184 ± 52.158077.744 ± 34.817781.027 ± 65.105098.733 ± 6.2562140.597 ± 41.7347128.943 ± 26.7782—62.007————————
C0D14 - BMS-813160185.926 ± 56.5866124.400 ± 52.1454260.786 ± 120.8954168.274 ± 72.7581158.238 ± 82.5905194.009 ± 50.1111283.842 ± 109.4518149.271 ± 72.0204—115.147————————
C0D14 - BMS-939429101.042 ± 27.504376.285 ± 30.5071145.662 ± 73.321591.490 ± 43.800687.068 ± 43.9667111.649 ± 32.4552————————————
SecondaryNumber of Participants Who Were Anti-Drug Antibody (ADA) Positive

The number of participants who are anti-drug antibody positive. ADA-positive participant is a participant with at least 1 ADA-positive sample relative to baseline after initiation of the treatment. ADA-positive sample is in a participant who is baseline ADA negative or with an ADA titer to be at least 4-fold or greater than baseline positive titer.

Time frame:
From first dose up to prespecified timepoints-C1D1, C1D15, C2D1, C3D1, C5D1, C9D1
Reported as:
Count of participants · Participants
Number of Participants Who Were Anti-Drug Antibody (ADA) Positive
ParticipantsPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Number of Participants Who Were Anti-Drug Antibody (ADA) Positive000000100000000000

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 5.5 years). SAEs and Other AEs were assessed from first dose to 100 days following last dose (up to approximately 3 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIR6/10 (60%)5/10 (50%)10/10 (100%)
Part 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRI6/8 (75%)5/8 (62.5%)8/8 (100%)
Part 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NAB8/10 (80%)5/10 (50%)9/10 (90%)
Part 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NAB8/11 (72.7%)7/11 (63.6%)11/11 (100%)
Part 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVO6/8 (75%)5/8 (62.5%)8/8 (100%)
Part 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVO6/7 (85.7%)6/7 (85.7%)7/7 (100%)
Part 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVO6/7 (85.7%)6/7 (85.7%)7/7 (100%)
Part 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVO7/11 (63.6%)6/11 (54.5%)10/11 (90.9%)
Part 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVO1/1 (100%)1/1 (100%)1/1 (100%)
Part 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVO2/2 (100%)2/2 (100%)2/2 (100%)
Part 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRI26/32 (81.3%)12/32 (37.5%)32/32 (100%)
Part 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRI28/32 (87.5%)12/32 (37.5%)31/32 (96.9%)
Part 2-Arm A-Cohort 1C: 2L CRC/FOLFIRI17/26 (65.4%)6/26 (23.1%)25/26 (96.2%)
Part 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NAB33/35 (94.3%)24/35 (68.6%)35/35 (100%)
Part 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVO34/35 (97.1%)22/35 (62.9%)34/35 (97.1%)
Part 2-Arm B-Cohort 3C: 1L PC/GEM/NAB26/32 (81.3%)15/32 (46.9%)31/32 (96.9%)
Part 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVO20/24 (83.3%)17/24 (70.8%)19/24 (79.2%)
Part 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO25/33 (75.8%)19/33 (57.6%)30/33 (90.9%)
Most frequent serious events
Showing 10 of 143
Most frequent serious events
EventPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Blood bilirubin increasedInvestigations0/100/80/100/110/80/71/71/111/10/21/320/320/260/350/350/320/241/33
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/100/80/100/110/83/75/74/111/12/21/320/320/260/352/351/327/248/33
General physical health deteriorationGeneral disorders0/100/80/100/110/80/70/70/110/11/20/320/320/260/350/350/320/240/33
Deep vein thrombosisVascular disorders0/100/80/100/110/80/70/70/110/11/20/321/320/261/350/350/322/240/33
DyspnoeaRespiratory, thoracic and mediastinal disorders0/100/82/100/111/80/70/70/110/10/20/320/320/261/352/351/321/240/33
NauseaGastrointestinal disorders0/101/80/102/110/80/70/70/110/10/20/320/320/262/351/351/323/240/33
PyrexiaGeneral disorders1/101/80/102/110/80/70/70/110/10/20/320/320/264/355/352/320/240/33
SepsisInfections and infestations0/100/80/102/110/80/70/70/110/10/21/320/320/265/352/351/321/240/33
RashSkin and subcutaneous tissue disorders0/100/80/102/110/80/70/70/110/10/20/320/320/260/350/350/320/240/33
Abdominal painGastrointestinal disorders1/101/81/101/110/80/71/70/110/10/23/320/320/262/353/352/323/242/33
Most frequent other events
Showing 10 of 250
Most frequent other events
EventPart 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVO
Sinus tachycardiaCardiac disorders0/100/80/101/110/80/73/70/111/10/21/320/320/260/351/351/321/241/33
Abdominal pain upperGastrointestinal disorders1/101/80/102/112/80/71/71/111/10/21/324/321/263/353/352/323/240/33
DiarrhoeaGastrointestinal disorders7/104/83/102/113/81/73/73/111/10/213/3214/3215/2615/3519/3513/326/248/33
VomitingGastrointestinal disorders3/101/84/103/111/81/75/72/111/11/26/3210/328/2610/3511/359/325/240/33
Non-cardiac chest painGeneral disorders0/100/80/101/110/80/70/70/111/10/23/322/320/262/352/350/321/241/33
Peripheral swellingGeneral disorders0/100/80/100/110/80/70/70/111/10/20/320/320/265/352/352/320/240/33
Amylase increasedInvestigations2/101/80/101/111/80/70/71/111/10/22/320/322/263/351/351/320/242/33
Lipase increasedInvestigations4/101/81/101/112/80/70/71/111/10/24/322/321/263/356/351/320/242/33
DyspnoeaRespiratory, thoracic and mediastinal disorders2/100/81/101/113/80/73/70/111/10/21/320/321/2610/359/356/323/243/33
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/100/80/100/110/80/70/70/111/10/20/321/321/261/353/351/320/241/33

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVOTotal
All Cohorts except Part 2-Arm C-Cohort 565.6 (54 to 83)53.3 (28 to 66)64.1 (54 to 80)62.7 (51 to 80)59.5 (48 to 76)61.7 (52 to 66)45.1 (33 to 57)60.5 (42 to 77)61.0 (61 to 61)50.0 (49 to 51)55.0 (29 to 76)58.9 (30 to 83)57.9 (37 to 77)65.9 (46 to 76)65.3 (43 to 85)65.5 (49 to 84)63.9 (34 to 77)—61.4 (28 to 85)
Part 2-Arm C-Cohort 5 only—————————————————55.0 (39 to 69)55.0 (39 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVOTotal
All Cohorts except Part 2-Arm C-Cohort 5 — Female3266233310131191515158—115
All Cohorts except Part 2-Arm C-Cohort 5 — Male764564480219211720201716—176
Part 2-Arm C-Cohort 5 only — Female—————————————————1818
Part 2-Arm C-Cohort 5 only — Male—————————————————1515
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVOTotal
All Cohorts except Part 2-Arm C-Cohort 5 — Hispanic or Latino00110003007222140—23
All Cohorts except Part 2-Arm C-Cohort 5 — Not Hispanic or Latino858987670221261728302421—227
All Cohorts except Part 2-Arm C-Cohort 5 — Unknown or Not Reported23110011104475443—41
Part 2-Arm C-Cohort 5 only — Hispanic or Latino—————————————————44
Part 2-Arm C-Cohort 5 only — Not Hispanic or Latino—————————————————2323
Part 2-Arm C-Cohort 5 only — Unknown or Not Reported—————————————————66
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1-Arm A-Cohort 1: 1L CRC/BMS300BID + FOLFIRIPart 1-Arm A-Cohort 2: 1L CRC/BMS600QD + FOLFIRIPart 1-Arm B-Cohort 1: 1L PC/BMS300BID + GEM/NABPart 1-Arm B-Cohort 2: 1L PC/BMS600QD + GEM/NABPart 1-Arm C-Cohort 1: 2/3L CRC MSS/BMS300BID + NIVOPart 1-Arm C-Cohort 2: 2/3L CRC MSS/BMS600QD + NIVOPart 1-Arm C-Cohort 3: 2/3L CRC MSS/BMS300QD + NIVOPart 1-Arm C-Cohort 4: 2/3L CRC MSS/BMS150QD + NIVOPart 1-Arm C-Cohort 5: 2L PC/BMS300BID + NIVOPart 1-Arm C-Cohort 6: 2L PC/BMS600QD + NIVOPart 2-Arm A-Cohort 1a: 2L CRC/BMS300BID + FOLFIRIPart 2-Arm A-Cohort 1b: 2L CRC/BMS150QD + FOLFIRIPart 2-Arm A-Cohort 1C: 2L CRC/FOLFIRIPart 2-Arm B-Cohort 3a: 1L PC/BMS300BID + GEM/NABPart 2-Arm B-Cohort 3b: 1L PC/BMS300BID + GEM/NAB + NIVOPart 2-Arm B-Cohort 3C: 1L PC/GEM/NABPart 2-Arm C-Cohort 4: 2L PC/BMS300BID + NIVOPart 2-Arm C-Cohort 5: 2/3L CRC MSS /BMS300BID + NIVOTotal
All Cohorts except Part 2-Arm C-Cohort 5 — American Indian or Alaska Native00000000000000000—0
All Cohorts except Part 2-Arm C-Cohort 5 — Asian13000102002212111—17
All Cohorts except Part 2-Arm C-Cohort 5 — Native Hawaiian or Other Pacific Islander00000000000000000—0
All Cohorts except Part 2-Arm C-Cohort 5 — Black or African American10000100001320020—10
All Cohorts except Part 2-Arm C-Cohort 5 — White84101185771228262232342722—254
All Cohorts except Part 2-Arm C-Cohort 5 — More than one race00000000000000000—0
All Cohorts except Part 2-Arm C-Cohort 5 — Unknown or Not Reported01000002001111021—10
Part 2-Arm C-Cohort 5 only — American Indian or Alaska Native—————————————————00
Part 2-Arm C-Cohort 5 only — Asian—————————————————11
Part 2-Arm C-Cohort 5 only — Native Hawaiian or Other Pacific Islander—————————————————00
Part 2-Arm C-Cohort 5 only — Black or African American—————————————————33
Part 2-Arm C-Cohort 5 only — White—————————————————2828
Part 2-Arm C-Cohort 5 only — More than one race—————————————————00
Part 2-Arm C-Cohort 5 only — Unknown or Not Reported—————————————————11
08

Study locations

40 sites
  • Local Institution - 0003
    Birmingham, Alabama 35249, United States
  • Local Institution - 0026
    Phoenix, Arizona 85054, United States
  • Local Institution - 0002
    Los Angeles, California 90033, United States
  • Local Institution - 0025
    Los Angeles, California 90033, United States
  • Local Institution - 0041
    Orange, California 92868-3201, United States
  • Local Institution - 0015
    Aurora, Colorado 80045, United States
  • Local Institution - 0018
    Washington D.C., District of Columbia 20007, United States
  • Local Institution - 0048
    Brooksville, Florida 34613, United States
  • Local Institution - 0047
    St. Petersburg, Florida 33705, United States
  • Local Institution - 0005
    Baltimore, Maryland 21287, United States
  • Local Institution - 0033
    Boston, Massachusetts 02114, United States
  • Local Institution - 0027
    Rochester, Minnesota 55905-0001, United States
  • Local Institution - 0039
    Hattiesburg, Mississippi 39401, United States
  • Local Institution - 0023
    St Louis, Missouri 63110, United States
  • Local Institution - 0004
    Hackensack, New Jersey 07601, United States
  • Local Institution - 0017
    New York, New York 10065, United States
  • Local Institution - 0024
    Rochester, New York 14642, United States
  • Local Institution - 0046
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0044
    Cleveland, Ohio 44106-5055, United States
  • Local Institution - 0021
    Cleveland, Ohio 44195, United States
  • Local Institution - 0037
    Allentown, Pennsylvania 18103, United States
  • Local Institution - 0014
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0020
    Philadelphia, Pennsylvania 19107, United States
  • Local Institution - 0045
    Charleston, South Carolina 29425, United States
  • Local Institution - 0034
    Nashville, Tennessee 37203, United States
  • Local Institution - 0038
    Nashville, Tennessee 37232, United States
  • Local Institution - 0016
    Salt Lake City, Utah 84112, United States
  • Local Institution - 0042
    Charlottesville, Virginia 22908, United States
  • Local Institution - 0028
    Clayton, Victoria 0, Australia
  • Local Institution - 0050
    Brussels, 1200, Belgium
  • Local Institution - 0051
    Edegem, 2650, Belgium
  • Local Institution - 0049
    Leuven, 3000, Belgium
  • Local Institution - 0013
    Edmonton, Alberta T6G 1Z2, Canada
  • Local Institution - 0012
    Ottawa, Ontario K1H 8L6, Canada
  • Local Institution - 0001
    Toronto, Ontario M5G 1X6, Canada
  • Local Institution - 0022
    Dresden, 01307, Germany
  • Local Institution - 0007
    Heidelberg, 69120, Germany
  • Local Institution - 0031
    Barcelona, 08003, Spain
  • Local Institution - 0032
    Madrid, 28046, Spain
  • Local Institution - 0030
    Majadahonda - Madrid, 28222, Spain
09

References and documents

Publications

  • Le DT, Folprecht G, Varghese AM, Gutierrez M, Noel M, Trikalinos NA, Chen E, Dayyani F, Davis SL, Ma WW, BasuMallick A, Garrido-Laguna I, Osawa M, O'Brien S, Novosiadly RD, Xu K, Greenawalt DM, Dutta S, Twyman Saint Victor C, Lenz HJ. Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. J Immunother Cancer. 2026 Jan 22;14(1):e011284. doi: 10.1136/jitc-2024-011284. PubMed 41571299 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Apr 2023, 67 months.

Results were first posted in Oct 2025, 2 years 6 months after primary completion.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's 67 months is above that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2017
First posted
Jun 14, 2017
StartActual
Aug 8, 2017
Primary completionActual
Apr 6, 2023
CompletionActual
Jun 14, 2023
Results first posted
Oct 9, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03184870
Responsible party
Sponsor
First posted
Jun 14, 2017
Start date
Aug 8, 2017
Primary completion
Apr 6, 2023
Completion
Jun 14, 2023
Results posted
Oct 9, 2025
Last update
Oct 9, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BMS-813160 · Albumin-Bound Paclitaxel · Gemcitabine · Fluorouracil · Leucovorin · Irinotecan

Start the discussion